Revenue surged 71% year-over-year to 359 mln PLN, with normalized EBITDA up 93% and strong growth in medical equipment and recurring service sales. Robust cash flow, improved margins, and expansion in robotic surgery and radio-pharmaceuticals support a positive outlook.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.